The Need for Multiple Doses of 400 mg Ketoconazole as a Precipitant Inhibitor of a CYP3A Substrate in an In Vivo Drug-Drug Interaction Study

被引：12
|
作者：
Oo, Charles [1 ]
Chen, Chi [1 ]
机构：
[1] Asubio Pharmaceut Inc, Rochelle Pk, NJ 07662 USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2009年 / 49卷 / 03期
关键词：
PHARMACOKINETICS; PREDICTION;
D O I：
10.1177/0091270008325931
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：368 / 369
页数：2
相关论文
共 33 条
  • [1] Evidence-Based Choice of Ritonavir as Index CYP3A Inhibitor in Drug-Drug Interaction Studies
    Greenblatt, David J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (02) : 152 - 156
  • [2] Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of Lemborexant
    Landry, Ishani
    Aluri, Jagadeesh
    Nakai, Kenya
    Hall, Nancy
    Miyajima, Yukiko
    Ueno, Takashi
    Dayal, Satish
    Filippov, Gleb
    Lalovic, Bojan
    Moline, Margaret
    Reyderman, Larisa
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (06): : 681 - 690
  • [3] The utility of CYP3A activity endogenous markers for evaluating drug-drug interaction between sildenafil and CYP3A inhibitors in healthy subjects
    Lee, Soyoung
    Kim, Andrew HyoungJin
    Yoon, Sumin
    Lee, Jieon
    Lee, Yujin
    Ji, Sang Chun
    Yoon, Seo Hyun
    Lee, SeungHwan
    Yu, Kyung-Sang
    Jang, In-Jin
    Cho, Joo-Youn
    DRUG METABOLISM AND PHARMACOKINETICS, 2021, 36
  • [4] A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies
    de Jong, Jan
    Hellemans, Peter
    De Wilde, Severijn
    Patricia, Daniel
    Masterson, Tara
    Manikhas, Georgii
    Myasnikov, Alexander
    Osmanov, Dzhelil
    Cordoba, Raul
    Panizo, Carlos
    de Zwart, Loeckie
    Snoeys, Jan
    Chauhan, Vijay
    Jiao, James
    Sukbuntherng, Juthamas
    Ouellet, Daniele
    LEUKEMIA & LYMPHOMA, 2018, 59 (12) : 2888 - 2895
  • [5] A Drug-Drug Interaction Study to Evaluate the Effect of TAS-303 on CYP3A Activity in the Small Intestine and Liver
    Kumagai, Yuji
    Fujita, Tomoe
    Maeda, Mika
    Sasaki, Yoshinobu
    Nagaoka, Makoto
    Huang, Jinhong
    Takenaka, Toru
    Kawai, Masaki
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (06) : 702 - 710
  • [6] Effect of the CYP3A Inhibitor Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Advanced Solid Tumors: A Prospective, Multicenter, Open-Label, Randomized, Two-Way Crossover Drug-Drug Interaction Study
    Venkatakrishnan, Karthik
    Rader, Michael
    Ramanathan, Ramesh K.
    Ramalingam, Suresh
    Chen, Eric
    Riordan, William
    Trepicchio, William
    Cooper, Michael
    Karol, Michael
    von Moltke, Lisa
    Neuwirth, Rachel
    Egorin, Merrill
    Chatta, Gurkamal
    CLINICAL THERAPEUTICS, 2009, 31 : 2444 - 2458
  • [7] CYP3A4-based drug-drug interaction: CYP3A4 substrates' pharmacokinetic properties and ketoconazole dose regimen effect
    Boulenc, Xavier
    Nicolas, Olivier
    Hermabessiere, Stephanie
    Zobouyan, Isabelle
    Martin, Valerie
    Donazzolo, Yves
    Ollier, Celine
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2016, 41 (01) : 45 - 54
  • [8] Drug-drug interaction study with itraconazole supplemented with physiologically based pharmacokinetic modelling to characterize the effect of CYP3A inhibitors on venglustat pharmacokinetics
    Li, Li
    Zhang, Yan-Yan
    Sharma, Jyoti
    Cartot-Cotton, Sylvaine
    Crawford, Nigel
    Macha, Sreeraj
    Li, Yi
    Sahi, Jasminder
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2025,
  • [9] An open-label study to explore the optimal design of CYP3A drug-drug interaction clinical trials in healthy Chinese people
    Chen, Jingcheng
    Li, Jiangshuo
    Wu, Jingxuan
    Song, Yuqin
    Li, Lijun
    Zhang, Jianxiong
    Dong, Ruihua
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2024, 12 (04):
  • [10] A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs
    Molenaar-Kuijsten, Laura
    Van Balen, Dorieke E. M.
    Beijnen, Jos H.
    Steeghs, Neeltje
    Huitema, Alwin D. R.
    FRONTIERS IN PHARMACOLOGY, 2021, 12
1234